Verquvo (vericiguat) / Bayer, Merck (MSD), Chong Kun Dang - LARVOL DELTA

Unveiling Heart Failure: Gender-Specific Insights and Innovations in Women's Cardiac Health. (PubMed, Curr Pharm Des) - "Moreover, it highlights advancements in pharmacological treatments, including ARNI, SGLT2 inhibitors, and novel therapeutic agents like vericiguat (for selective patients) and omecamtiv mecarbil (modest benefits), while addressing the potential of lifestyle interventions, such as diet, exercise, in mitigating HF risk. Artificial intelligence emerges as a promising potential for enhancing diagnostic precision, patient management, and outcome prediction, heralding a new era in HF care. By integrating gender-specific research and innovations, this study aims to refine strategies for improving women's cardiac health, ultimately reducing the global burden of HF."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation

Use of vericiguat in a patient with heart failure with reduced ejection fraction and transthyretin cardiac amyloidosis: a helpful therapeutic opportunity. (PubMed, Minerva Cardiol Angiol) - No abstract available

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Heart Failure

Pulmonary Arterial Pressure Monitoring of the Pulmonary Hemodynamics With Vericiguat in Heart Failure With Reduced Ejection Fraction. (PubMed, Am J Ther) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome (clinicaltrials.gov) - P2 | N=104 | Active, not recruiting | Sponsor: Charite University, Berlin, Germany | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Oct 2025 ➔ Apr 2026

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety and efficacy of Vericiguat 5mg initiation in combination with guideline-directed medical therapy in the treatment of Heart failure with reduced ejection fraction (ChiCTR) - P=N/A | N=140 | Completed | Sponsor: The First Hospital of Jilin University; The first hospital of Jilin University

New trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy-Induced Heart Failure by Multiple Mechanisms. (PubMed, Eur J Pharmacol) - "This study for the first time demonstrates that in addition to the direct effect of cGMP signaling, vericiguat may target and regulate HDAC1 expression and may repair sarcoplasmic reticulum swelling and enhance autophagy in hypertrophic hearts. We conclude that the preventive effect of vericiguat on the HF through multiple mechanisms and the results emphasize the potential clinical usefulness of vericiguat in the prevention of the progress of HF."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • HDAC1

Vericiguat in Routine Practice: Insights from a Prospective Real-World Study in Chinese Population. (PubMed, Cardiology) - No abstract available

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

COMPARATIVE EFFECTIVENESS OF VERICIGUAT VS IVABRADINE IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A PROPENSITY SCORE-MATCHED ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure

Expanding Beyond Foundational GDMT: Adjunctive Pharmacological Agents to Curb Transition From Stage C to D (ISHLT 2026) - "This presentation will review the landscape of medical therapies that may serve as an adjunct to the traditional four-tier GDMT for HfrEF, with a focus on their incremental impact on risk reduction. In particular focused will be on the use of ARNI for advanced heart failure, as well as the integration of SGLT2 inhibitors, vericiguat, ivabradine, GLP-1agonists into contemporary treatment strategies."

Cardiovascular • Congestive Heart Failure • Heart Failure

Low-Dose Vericiguat in Heart Failure With Reduced Ejection Fraction: A Case Report. (PubMed, Cureus) - "However, these observations may also reflect other contributing factors, and causality cannot be established. Further studies are needed to better define the long-term safety and efficacy of lower-dose vericiguat in broader patient populations."

Journal • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease

VERICIGUAT IN HEART FAILURE WITH REDUCED EJECTION FRACTION: META-ANALYSIS OF CLINICAL OUTCOMES AND SAFETY PROFILE (ACC 2026) - "Abstract is embargoed at this time."

Clinical data • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

Efficacy and Safety of Vericiguat in the Treatment of HFrEF Patients with Different NT-proBNP Levels (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: Jilin Province FAW General Hospital; Jilin Province FAW General Hospital

New trial • Cardiovascular • Heart Failure

Prognostic Value of Angiography-Derived Microcirculatory Resistance and Vericiguat Therapy in Dilated Cardiomyopathy with Reduced Ejection Fraction. (PubMed, Can J Cardiol) - "AMR may be a powerful independent predictor of poor prognosis in DCMrEF patients, with LAD-AMR showing potential for greater predictive value. Vericiguat may represent a potential precision-targeted agent for the high risk of heart failure mediated by microcirculatory dysfunction."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Clinical and Echocardiographic Effects of Vericiguat Therapy in Advanced Heart Failure Patients Undergoing LVAD Support (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Metastases • Cardiovascular • Congestive Heart Failure • Heart Failure

Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice. (PubMed, Am Heart J Plus) - "HR 0.82, 95% C.I. (0.58, 1.16). Vericiguat users initiated on the 5 mg/day dose were considerably more likely to reach the target dose of 10 mg/day vs. those started on the recommended 2.5 mg/day dose, without excess risk of hypotension or syncope."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

VERICIGUAT IN HEART FAILURE: BENEFIT IN HFREF AND POTENTIAL HARM IN HFPEF BASED ON A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

1058. SGLT2, Finerenone and Vericiguat in the Modern HFpEF Landscape (ACC 2026) - No abstract available

Cardiovascular

Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction. (PubMed, J Cardiovasc Dev Dis) - "In patients with HFrEF and recent worsening, the addition of vericiguat to GDMT may be associated with reverse myocardial remodeling."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China (clinicaltrials.gov) - P=N/A | N=2400 | Completed | Sponsor: Bayer | Recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

EARLY VERICIGUAT ADJUNCTIVE THERAPY IMPROVES LEFT VENTRICULAR REMODELING IN POST-AMI PATIENTS WITH REDUCED EJECTION FRACTION (ACC 2026) - "Abstract is embargoed at this time."

Clinical

COST-EFFECTIVENESS OF VERICIGUAT IN PATIENTS WITH HFREF WITHOUT RECENT HEART FAILURE WORSENING: INSIGHTS FROM THE VICTOR TRIAL (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cost effectiveness • HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure

ADVERSE EVENTS OF VERICIGUAT IN CARDIAC FAILURE PATIENTS: A REAL-WORLD AND PHARMACOVIGILANCE DATABASE ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Adverse events • Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management. (PubMed, Cardiol Ther) - "This study enrolled high-risk patients with recent decompensation event consistent with the VICTORIA trial. The usage of standard of care (SoC) was as per current clinical practice in HF; VERINA enrolled 52.7% on ARNI compared to 14.5% in VICTORIA and 75.6% on SGLT2i compared to 2% in VICTORIA. Safety data did not reveal any new safety signals or adverse trends in the interim analysis."

Journal • P4 data • Cardiovascular • Congestive Heart Failure • Heart Failure

The guanylate cyclase stimulator vericiguat: Insights and adverse events from a FAERS-based pharmacovigilance study. (PubMed, Int J Clin Pharmacol Ther) - "Our analysis provides a comprehensive safety assessment of vericiguat. Most of these results align with findings from previous studies. In addition, our data revealed several new adverse events. This study provides valuable insights that can inform future research and clinical practice."

Adverse events • Journal • Cardiovascular • Congestive Heart Failure • Dyspepsia • Heart Failure • Hematological Disorders • Hypotension • Renal Disease

Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials. (PubMed, JACC Adv) - "IV iron and GLP1 agonists or GLP1/GIP agonists improved both QOL and exercise capacity in patients with HF. SGLT2 inhibitors significantly improved QOL but had no significant effect on exercise capacity."

Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure